Arcturus Therapeutics Inc (ARCT): Price-to-Sales Ratio

Corporate company logo of Arcturus Pharma (ARCT)

Arcturus Therapeutics' critical dependence on external CRO/CMO contractors for mRNA drug production drives its price action. The volatility of the P/S ratio visualizes this process, where the value of 11.10 reflects the metric's balance. Stability is underpinned by a US-based R&D foundation and government contracts, while the risks of a narrow portfolio are offset by royalties from global pharma partners.

ARCT: Arcturus Therapeutics P/S Multiple 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Arcturus Pharma (ARCT)

- share price and consensus valuation forecast:
Price Performance Chart arcturusrx.com|ARCT - Price Target Chart
- stock exchange capitalization data:
Market Valuation Arcturus Pharma|ARCT - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Arcturus Therapeutics|ARCT - Book Capitalization|Market Capitalization to Book Value Ratio arcturusrx.com|ARCT - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Arcturus Therapeutics|ARCT - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Arcturus Corp|ARCT - Company Aggregate Debts|Debts to Book Capitalization Arcturus Pharma|ARCT - Company Long-Term Debts|Company Short-Term Debts Arcturus Therapeutics|Intermediate Coverage Ratio arcturusrx.com
- earnings and valuation multiples information:
ARCT - Net Profit|Future Profit Arcturus Therapeutics|ARCT - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Arcturus Therapeutics Inc|ARCT - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Arcturus Pharma|ARCT - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Arcturus Therapeutics|ARCT - Net earnings per share for the last 12 months|Quarterly EPS earnings growth arcturusrx.com|ARCT - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Arcturus Therapeutics
- issuer revenue and sales details:
ARCT - Company Sales|Company Future Revenue arcturusrx.com|ARCT - Market Cap to Revenue|Price to Expected Revenue Ratio Arcturus Pharma
General company analysis:ARCT arcturusrx.com
Finished products of Arcturus Therapeutics

Professional asset selection is based on finding a balance between market value and actual revenue generation to exclude overvalued securities. By analyzing price-to-sales dynamics, an investor assesses the ratio of market capitalization to sales volume, which for Arcturus Therapeutics (ARCT) is critically important given the dependence of income on Japanese royalties and the efficiency of R&D cost management during the development of mRNA therapies.

Competing companies

VRTX (vrtx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc.) - Price-to-Sales Ratio|United Therapeutics Corp. - P/S Multiple|Market Capitalization-to-Revenue Ratio BMRN (BioMarin Corp)|BBIO: P/S Multiple|BGM Group (BGM) - P/S Multiple|Price-to-Revenue Ratio Cogent Biosciences, Inc.|XERS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Keros Pharma (KROS)|Market Cap to Revenue Eton Corp ETON|P/S Multiple KMDA (Kamada Ltd.)|P/S Multiple fulcrumtx.com FULC|Abeona - P/S Multiple|MREO - P/S Multiple|Protalix (PLX) - Price-to-Revenue Ratio|Pliant Therapeutics, Inc. - Market Capitalization-to-Revenue Ratio|APLT (Applied Therapeutics) - P/S Multiple|Market Cap to Revenue aileronrx.com (RNTX)|Market Cap to Revenue GELS (Gelteq Limited)|Market Cap to Sales Volume AYTU|Chemomab Therapeutics Ltd. - Market Cap to Revenue|P/S Multiple SRx Health Solutions Inc SRXH|PLRZ - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio AEZS (Aeterna Zentaris)|CYTH (Cyclo Therapeutics, Inc.) - Market Cap to Revenue|Inozyme Pharma (INZY) - P/S Multiple|Price-to-Revenue Ratio Reneo Pharma|COSCIENS Bio (CSCI) - Price-to-Revenue Coefficient